← All trials
NCT01817959
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2012
- Primary completion
- Oct 1, 2016
- Completion date
- Oct 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Dompe PharmaceuticalsLead sponsor
- University of ChicagoOverall official - principal investigator
- Uppsala UniversityOverall official - principal investigator
- Lund UniversityOverall official - principal investigator
- University of GothenburgOverall official - principal investigator
- Vita-Salute University of Milano. ItalyOverall official - principal investigator
- Karolinska InstituteOverall official - principal investigator
- University of MilanOverall official - principal investigator
- Newcastle UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.